COGNIGY
17.12.2020 06:03:08 CET | Business Wire | Press release
Cognigy , a global leader in Conversational AI, and Telekom , a leading telecommunications provider, today announced a new partnership aimed at improving the customer journey through greater automation in customer service. With its Conversational AI Suite, Telekom offers artificial intelligence (AI) solutions individually tailored to customer concerns in collaboration with leading technology partners.
“Our AI solutions support the customer journey in customer service from start to finish by handling frequently occurring customer concerns in an automated and successful way. This reduces the customer service staff’s workload and cuts costs,” Waldemar Mach, Product Manager UC & AI Managed Solutions, Telekom Germany GmbH, explains. “Cognigy.AI is a perfect fit for our solution portfolio, both functionally and technically, as it is highly integrative, extremely flexible in its use with both voice and chat services and designed to handle large volumes of dialog.”
“We are pleased to have found another strong partner who is enthusiastic about Cognigy.AI. The partnership with Telekom underscores Cognigy’s proficiency in the area of smart automation of customer communications,” said Marc Schneider, VP of Partnerships EMEA at Cognigy. “Telekom’s expertise in the areas of service, operations, and project management, paired with our easy-to-use low-code platform, guarantees trouble-free, GDPR (General Data Protection Regulation)-compliant projects and fast ROIs.”
First Conversational AI Project for the Telekom Baskets
In a first joint Cognigy.AI project, Telekom improved the digital experience of the basketball team it sponsors, the Telekom Baskets. The aim was to employ a digital assistant and make fan interaction more efficient, more emotional, and unlimited in terms of time. A particular highlight of the solution is the digitization of the Baskets’ mascot. “Bonni” was measured and filmed in various poses to create a likable 3D avatar with high recognition value for the fans.
Fans can chat with the virtual mascot and get information from it at www.telekom-baskets-bonn.de anytime. Bonni provides support with any queries relating to tickets, the fan store, the match schedule, the team, or directions to the Telekom Dome. The avatar also reacts to events in real time, for example jumping in the air when a positive message is received, clapping its hands, or cheering, which lends an emotional touch to the interaction. The team behind Bonni can adapt and expand chat dialogs constantly, thanks to the intuitive usability of Cognigy.AI.
In addition to Telekom, Cognigy offers its customers a broad network of skilled local and global implementation and IT system partners with relevant industry and subject specializations. Find a qualified partner on the Cognigy partner network page: www.cognigy.com/partner
Cognigy offers all business users the opportunity to experience Conversational AI for themselves. Try a personalized demo for your own use case or try a free test environment .
About Cognigy
Cognigy is a global leader in Conversational AI to support customer service automation. Its low-code platform, Cognigy.AI, enables enterprises to automate contact centers for customer and employee communications using intelligent voice- and chatbots. With precise, reliable intent recognition, human-like dialogs and seamless integration into backend systems, Cognigy.AI creates superior user experiences and helps companies reduce support costs. Cognigy.AI is available in SaaS and on-premise environments and supports conversations in any language and on any channel including phone, webchat, SMS and mobile apps. Cognigy’s worldwide client portfolio includes Daimler, Bosch, Henkel, Lufthansa, Salzburg AG and many more. Learn more at cognigy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216006018/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom